-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NO/kuSCNfVgiTvum4eXTkqsE7Ylbsz6NnFrug2nmrotJ8d/ZA/a4AV3xDutq9OYc
 QaIF9B8grM0+pzu88CoGmA==

<SEC-DOCUMENT>0000890163-07-000401.txt : 20070626
<SEC-HEADER>0000890163-07-000401.hdr.sgml : 20070626
<ACCEPTANCE-DATETIME>20070626130022
ACCESSION NUMBER:		0000890163-07-000401
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070626
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070626
DATE AS OF CHANGE:		20070626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PIPEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		07940599

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s11-7490_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><b><font SIZE=5>UNITED STATES</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=5>SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>WASHINGTON, D.C. 20549</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><b><font SIZE=5>FORM 8-K</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><b><font SIZE=2>CURRENT REPORT</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><font size=2>Date of Report (Date of earliest event reported): June 26, 2007</font></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><font size=2>Pipex Pharmaceuticals, Inc.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Exact name of Registrant as specified in its charter)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="100%" style='border-collapse:collapse'>
    <tr style=' height:39.2pt'>
        <td width="33%" valign=top style=' height:39.2pt'>
            <p style='margin-left:3.0pt;text-indent:-3.0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>Delaware</font></p>
<p style='margin-left:3.0pt;text-indent:-3.0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>(State or other jurisdiction of</font></p>
<p style='margin-left:3.0pt;text-indent:-3.0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>incorporation)</font></p> </td>
        <td width="33%" valign=top style=' height:39.2pt'>
            <p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>01-12584</font></p>
<p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>(Commission</font></p>
<p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>File Number)</font></p> </td>
        <td width="33%" style='height:39.2pt'>
            <p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>13-3808303</font><br> <font size=2>(IRS Employer</font></p>
<p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>Identification Number)</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>3985 Research Park Drive</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>Ann Arbor, MI 48108</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>(Address of principal executive offices) (Zip Code)</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><font size=2>(734) 332-7800</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>(Registrant's telephone number, including area code)</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:left;'><font size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:</font></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="101%" style='border-collapse:collapse'>
    <tr style='height:13.9pt'>
        <td width="5%" valign=top style=' height:13.9pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:13.9pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> </td> </tr>
    <tr style='height:13.15pt'>
        <td width="5%" valign=top style=' height:13.15pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:13.15pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p> </td> </tr>
    <tr style='height:27.8pt'>
        <td width="5%" valign=top style=' height:27.8pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:27.8pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act </font><br> <font size=2>(17 CFR 240.14d-2(b))</font></p> </td> </tr>
    <tr style='height:27.05pt'>
        <td width="5%" valign=top style=' height:27.05pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:27.05pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act </font><br> <font size=2>(17 CFR 240.13e-4(c))</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Item 3.01 &#150; Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.58in;text-align:left;'><font size=2>The common stock of the Registrant began trading on the American Stock Exchange at the opening of the market on June 26, 2007 under the ticker symbol &#147;PP.&#148;  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>



<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><FONT SIZE="2"><B>Item 9.01 Financial Statements and Exhibits.</B> </FONT></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" STYLE="border-collapse:collapse">
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt;" WIDTH="10%">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(d)</font></p> </td>
        <TD WIDTH="82%" VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Exhibits.  <BR><BR></font></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt;">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b>&nbsp;</b></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Exhibit 99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated June 26, 2007.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b>&nbsp;</b></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:12pt; margin-top:6pt;text-align:center;'><font SIZE=2>SIGNATURE</font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="100%" style='border-collapse:collapse'>
    <tr >
        <td width="50%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="50%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:12.0pt'><font SIZE=2>PIPEX PHARMACEUTICALS, INC.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="50%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Dated: June 26, 2007</font>             </p> </td>
        <td width="50%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>By:  </font><u><font size=2>/s/ Steve H. Kanzer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></u></p>
<p style='margin-left:0pt;text-indent:.2in;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;Steve H. Kanzer, CEO</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:2.5in; text-indent:0.5in;text-align:left;'><font size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>s11-7490_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><img src="img1.jpg"><br> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=3>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=5>Pipex Pharmaceuticals to begin Trading Today on the American Stock Exchange</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=3>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>ANN ARBOR, MI &#151; June 26, 2007 -- Pipex Pharmaceuticals, Inc. ("Pipex") (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage oral drug candidates for the treatment of neurologic and fibrotic diseases, announced that its common stock will begin trading today on the American Stock Exchange ("AMEX").  Pipex&#146;s common stock will be traded under the ticker symbol &#147;PP.&#148;  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Steve H. Kanzer, Chairman and Chief Executive Officer of Pipex, stated, "As previously announced, we believe this is a significant step for Pipex and its shareholders.  We believe this new listing will broaden our visibility and marketability which will enable Pipex to expand its shareholder base as we move forward toward our filing of our New Drug Application (NDA) for COPREXA for the treatment of neurologic Wilson&#146;s disease, an orphan genetic disease."</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:left;'><b><font size=2>About Pipex Pharmaceuticals, Inc. </font></b></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>Pipex Pharmaceuticals, Inc. ("Pipex") is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Pipex's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). For further information please visit www.pipexpharma.com.</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements that may reflect Pipex's current expectations about its future results, performance, prospects and opportunities, including our listing on the American Stock Exchange and building shareholder value due to that listing. Where possible, Pipex has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, including the risks set forth in Pipex's filings with the Securities and Exchange Commission. We cannot assure you that we will be able to successfully develop or
commercialize products based on our </font></p>

<p style=' margin-bottom:0pt; margin-top:5pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>technologies, including COPREXA, TRIMESTA, Anti-CD4 802-2, CORRECTA, EFFIRMA and SOLOVAX, particularly in light of the significant uncertainty inherent in developing, manufacturing and conducting preclinical and clinical trials of new pharmaceuticals and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our cash expenditures will not exceed projected levels, that we will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that we will be able to successfully obtain any further grants and awards, maintain our existing grants which are subject to performance, that we will be able to patent, register or protect our technology from
challenge and products from competition or maintain or expand our license agreements with our current licensors, or that our business strategy will be successful. All forward-looking statements made in this press release are made as of the date hereof, and Pipex assumes no obligation to update the forward-looking statements included in this news release whether as a result of new information, future events, or otherwise, other than as required by law. </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><i><font size=2>Contact:</font></i></p>


<table border="0" cellspacing=0 cellpadding=0 width="231" style='margin-left:15.0pt;border-collapse:collapse'>
    <tr >
        <td width="100%" valign=top >
            <p ><font size=2>For Further Information Contact:</font></p></td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="267" style='margin-left:15.0pt;border-collapse:collapse'>
    <tr >
        <td  colspan="2" valign=top >
            <p ><font size=2>Steve H. Kanzer, CPA, Esq.</font></p></td>
        <td  width="25%">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td> </tr>
    <tr >
        <td  colspan="3" valign=top >
            <p ><font size=2>Chairman and Chief Executive Officer</font></p></td> </tr>
    <tr >
        <td width="45%" valign=top >
            <p ><font size=2>(734) 332-7800</font></p></td>
        <td   colspan="2">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td> </tr>
    <tr>
        <td width="120" ></td>

        <td width="80" ></td>

        <td width="67" ></td> </tr> </table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="267" style='margin-left:15.0pt;border-collapse:collapse'>
    <tr >
        <td  colspan="3" valign=top >
            <p ><font size=2>Thomas Redington (investor relations)</font></p></td> </tr>
    <tr >
        <td width="43%" valign=top >
            <p ><font size=2>Redington Inc.</font></p></td>
        <td   colspan="2">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td> </tr>
    <tr >
        <td  colspan="2" valign=top >
            <p ><font size=2>(203) 222-7399</font></p></td>
        <td  width="55%">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td> </tr>
    <tr>
        <td width="115" ></td>

        <td width="5" ></td>

        <td width="147" ></td> </tr> </table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!G`9(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDH`6BBB@`HI*6@`I**\VUSQ-K
MEIJ>H10:@Z1PS,J`1IA1V'(II7&E<]*HJ&U8O;1.QRS(I)]\5+2$+1110`44
M4E`"T4E+0`444E`"T444`%%%%`!1110`444E`"T4E+0`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2'I2T4`><>)]7O+7Q
M'>0KK-Q;1H$V1I(`!\HSVK$;Q%J8)QK]R0#P?.'^%>N/:V\CEY((G8]2R`FD
M^Q6A_P"76'_OV*KF\_R_R&G;H>1CQ'JAS_Q/KKZB84G_``D6J8YUZZX])A7K
MOV*T_P"?6'_OV*/L5I_SZP_]^Q1S>?Y?Y%<R['F.G>*]>@=634!>K_SRG`(;
M_@0Y!KT+0]:M]<L!<P@HRG;+$WWHV]#6+XPT"S&ES:E;01P7-OART:A=ZYY!
M]:R?!T[0^)C&O"7=N=XS_$O0_D34WN]26T>A5Y+XB5CJVJOF',<[8#6L39Z=
M25S7K5>0>(V/]NZHH/6=ZJ+M^'YCBKGK-F/]$A_ZYK_*LKQA<2VOANYG@N&M
MY%*8D5MI'SCO6M:?\></_7-?Y5(Z)(I5U#*>H89%):,D\@DUZ]!PFOWK?]MS
M49U_4\`'6[WN?^/@UZ_]DM_^?>+_`+X%`M;<=((_^^!3OYO\/\BE*W0\?.O:
ME_T&KWGI_I#?XT^+Q!J@E79K=X&ST,VX?D<UZ]]F@_YX1_\`?`J&YTRQNXC%
M/:02(>"&C%'-Y_E_D/F78Y+0/&=S]HAM=8VNLK;8[I%VC)Z!QTY]17;CI7E6
MM:3'IVI7NF*&:`*'BR<[5(Z?@?TKT/P]=O?>'K"YD)+O"NXD=2."?TJ+D7U(
M/$7B"+0[9,1^==3$B&$-C=ZDGL!7GVH>)];GE;S]4DB'_/.`B-5]@1R?SJ[X
MGN3+XDU&=_F%LJPH#T`QD_F2:U$MH?"_A:#4X[*WNKZ=DWO/T&_G`/8"J5[V
M7]?>5%KL<>=6OC@'5K_(Y_X^I!_6E_M:^'35+[_P+D_QKHW\=ZI&VU],T\>^
M6IO_``L#4^^G:?\`FU.Z_F_&/^1IK_*<_'JMRY^?5]07Z73_`.-=+X*O))_$
M/EG4+JX3[.Q*S3.PSD<X--3QYJLC;4TZPX]2U;'ASQ+?:IK'V*[M+2(>29-T
M).>"!CGZT7WUO]WZ(SEOJK'43DBWD(/(0_RKR&/4I6MD,NL:BDA&2!<2<'\Z
M]BZT@11T4#\*E.R_K];DGC<FI78(V:I?LOK]JD_QJ:U\0:K:ONMM6N<]2LLA
MD!_!LUZ]M7T'Y5FZUH=EJ]G)'-"GF8)CEVC<C=B#33??\O\`(TYUV.1E^(-X
MVFB..U1+TG#3=8P/[P7KGV/ZUSUQKFIW$Q:?5[MG]$E*`?@N,57AA-Q/#;@[
M7ED6+<!G:2<9_6O7M-TJRTN!8;2WCC4#!(4;F/J3W-"D_3^O,;Y8]+GE"ZK.
M`"^K7Z_]O,G/ZU8MM2E^UVHCU6_D8SQ@JUQ(006%>MX'H*-H]!23=[W_`"_R
M,V[A2T44""BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"D/
M`I:2@#`?QQH".R&[DW(2"!`_4'![4W_A._#W_/W)_P"`\G^%<(WF$ND6-TET
MT8)Z#+XY_.M5_`6NOD^;8`G_`*:/_P#$T^KT_'_@#C9[LZ;_`(3KP[_S^/\`
M^`\G^%)_PG?A_.!<RY_Z]W_PKF?^$`UPX_>6/_?U_P#XF@?#_6\_ZVQ7W$C_
M`/Q-&G;\?^`7RP[ECQ'XNCUFU.G:?%*L,C#S9I!MRHYP!U_&I?`]DUSJLVH@
M$P6\9AC;^\YQNQ]`/UIUC\/I?,!U#4`T?>*!",^VX]OH*[.TL[>QMDMK6)8H
M8QA$4<`4B&ET)J\@\2@G7-4(''GOS7K]<+JO@S5K[4+V>&6S6*YD+`.6W`>^
M!37^7YCB[':VG_'G#_US7^55-6URPT1(GOI'02L539&7R0,]A5VW0QP1HW)5
M0./I7)^/1\VE]?\`6OT_W:7FR'HB[_PGOA__`)^)OQMW_P`*#X]\/CK<R_A`
M_P#A7':=H&H^(#<&TGMD6WDV-YNX$G&>P/:KP^'NL=[NR_-_\*:]/Q_X!HE&
MVK.B_P"$]\/_`//S+_WX?_"H;CXA:*B'R!<W#XX58BH/XG&*P_\`A7NKG/\`
MIED/^^_\*='\.M2W`R:A:H/58V8_KBGIV_'_`(`6AW,>[N[K4[V:Z>,F]O6"
M10QG('91^`ZFO4-*LAIVE6MD&W>1$J%O4@<G\ZS="\)V>C/]H+M<W9&/.D`&
MWU"CM_.MT=*DC2^AYUXOLFLM>EF88M]14$-V$@7!!_#G\ZBMO$%C+HJ:)K\%
MRT,!&R>W/)`Z9[\=.*]!U#3K75+1K6\A66%^JGL>Q!['WKCKKX=RB5C9ZG^[
MS\JW$>Y@/]X'G\J$[,<5'J9FWP*<?/JIS_UTH*^!1QNU3_Q^K:_#S4A_R_V@
M_P"V;4?\*[U+_H(6O_?MJJ_E^/\`P"_=[E7'@@#C^U_P#UL^%?\`A&_[8/\`
M9(OQ<^2<_:`VW;D9Z_A5-/`.JQ_=O[//KY;_`.-:WA_PO?Z3JOVRZNX)E$)C
M`C1@>2#W/M1?^K_\`B7D=0[!$+'H!DUS(^(.B$9"WA';_1FYKI95+QNHZD$5
MPD?@35XXEB&I6>U?^F3?XU*V$:W_``L'1,X*WF?>W-9VL^/8YK22WTNWF#R*
M5\^9=H3/<#J34+?#[4G^]J-J?^V3?XU);_#F0R#[5J@"=Q##@GZ$DX_*G\OQ
M_P"`7[G<XM3L<*DFQTP5(/S*1T-=W8?$.W$"IJ5G<),!AGA4.C'UZY'TK8D\
M(:-)I:Z?]DV1H=RR*?W@;NV[N?KQ7/S?#F?S"8-40KGCS8#G'N0?Z"I6FF_]
M?,IRC+<U!\0-%/1+P_2W/%/C\=Z3)+'&(KT&1PB[K<@9)Q6,GP^U&/&W5+<?
M]L#_`(U/'X&O_.A>74H&6.19"!"03@Y]:K2^WX_\`S=NAVU+24M(04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4AI:0TF!Y*O,\?I]O\`
M3_II7K5<E_P@<?V@2G5;@JLWFA#&N,[MV*ZT=.:I_JQ)6%HHHI#"BBB@`HHH
MH`*Y#QX1G2SG&)F[?[-=?6/K^@)KB0*UU+;&!BP:,`DY&.]'=>HFKJQC_#_[
MFJ<$?Z0O_H(KI=3OO[.L'NO*:8J54(I`+%F"CD^YJEX?T!-`CG1+F6X\]P[-
M(H!!`QVJUK.GG5-,DLPRCS&0G=G&`X)''L*K2^I4;75R.RU8W+W<,]J]M<6@
M#21E@P(()!!'T-$&M07']G;%.;]2RC<"4^3=S_*IH-,M;.VFALX4A\W.XCDL
M<8R3U-9UCX:AL7TJ6&*VCELT*S/''@R93;U^O/-/W2O=U+EYK$-GJMII[QNS
M76?W@^['_=W?4@@?2C4-2FM;N"UMK)KJ69&?`D5``N`>O^\*I:CX<EOY[N[^
MV21W#%#;!7(1-G*;AW^;)_&K&IZ%#JU[!+>(DD,<,D90YSEMO(/X&CW=!^[H
M)+X@A3PV=;CMY9(PN?)&-Y.[:1Z9S2R^(;5+K3+>-'E_M(91EQA%VY!;Z]*!
MI4Y\.PZ8\D7FQ"-=ZKA2%8'I[@?G5.U\,RVUVDWVE76*\\R)2/N0A7P@^C.?
MPH]T:4-31U#6(=.O;.UDC=S=/MW+TC'`!;V)('XT[4=3-G-!;06S7-U<;C'$
MK!>%^\Q)Z`9'YBJ.J>'6U6XNIY+N2-GB6.W$;E0NWY@6'?YN?P%6;ZPO9+BR
MO[9X?M=LC(ZR9".K`;AD<CE011:.@K1T%FUCR=%;46LYE=6"&!\*P;<%QGIC
M)Z],5-;7MQ);2S75G]G\L$A1*K[@!GMTJI>Z9>WWAZ2RN)X9KJ1@S%E(CX<-
MMP.<8&/6I]/LI8;.6VFM[2W1\[5M2<<CDG('-+2PO=L+#JL<PT\B-Q]OC+ID
MCY0%W<_G40U:[.L_V=_9C8"[_.\Y<;,XW8Z_A4.G:5?PS6(NY+?RM/B,<1BW
M;I,@*"<].!TYYJ_]B?\`MHWV]=AMA#M[YW9S1H#Y4.BO5EU*>R",&@C20L>A
M#%@/_035*WUUKFX0QV$YLI93$ET"""P)&2O4+D$9JU#9/%K%U>EU*3PQ1A>X
M*ER?_0A5*QTW4[$Q6<5S`MA#*SA@"960DD(1T')Z^@HT#W2S>:S#9:I9V#QN
MS71(WK]V/^[N^IX%3R7JQZC!9%&+31NX;L-N/_BJR]2\.2:A/=W1O)(YWV?9
M@KD(FSYEW#O\V35K4+._?4+2]L_LQ>&-T=)F8`[MO((!_NT[(+1T'ZKJPTUK
M:)8#-/=.4B3>$&0"3ECP.!^-6K.X>YMEEDMY+=SD-')C*D'';@CWJEJEC=7]
MI"ABLYL<S6]PNZ-^.QQD$'H<4_0].DTO31;2R!SO9@JDE8P3D(N><#IS2TL#
MMR^9HT4E+4D!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
21110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
